SangStat regulatory update

SANG today was to announce that it has received European Patent No. 510949 covering its Xenoject platform technology for developing drugs that provoke the immune system to reject undesirable cells, such as infected or cancerous cells.

Read the full 365 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE